Payment overview · 2025
General Payments
$65.59
3 reported records · 2 companies
Healthcare provider profile · identity verified
David C Nelson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SIOUX FALLS, SD · NPI 1538164066
Verified facts
What the public records show
CMS Open Payments records show David C Nelson, M.D. received $65.59 in general payments during 2025 across 3 reported records.
Amgen Inc. accounted for 77.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.06 | 77.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.53 | 22.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.59 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.06 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 225 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 886 | 209 |
| Omeprazole | Omeprazole | 653 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 488 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 440 | 114 |
| Furosemide | Furosemide | 420 | 123 |
| Lisinopril | Lisinopril | 394 | 101 |
| Losartan Potassium | Losartan Potassium | 390 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 95 |
| Gabapentin | Gabapentin | 357 | 86 |
| Potassium Chloride | Potassium Chloride | 288 | 62 |
| Tramadol Hcl | Tramadol Hcl | 260 | 51 |
| Simvastatin | Simvastatin | 258 | 64 |
| Metformin Hcl | Metformin Hcl | 228 | 61 |
| Eliquis | Apixaban | 225 | 40 |
| Prednisone | Prednisone | 213 | 111 |
| Trazodone Hcl | Trazodone Hcl | 213 | 67 |
| Sertraline Hcl | Sertraline Hcl | 201 | 55 |
| Azithromycin | Azithromycin | 186 | 149 |
| Allopurinol | Allopurinol | 184 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 51 |
| Donepezil Hcl | Donepezil Hcl | 180 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 37 |
| Metformin Hcl Er | Metformin Hcl | 159 | 41 |
| Warfarin Sodium | Warfarin Sodium | 155 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 34 |
| Lorazepam | Lorazepam | 148 | 40 |
| Carvedilol | Carvedilol | 141 | 29 |
| Meloxicam | Meloxicam | 135 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 30 |
| Clonazepam | Clonazepam | 133 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 42 |
| Mirtazapine | Mirtazapine | 131 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 131 | 31 |
| Glipizide Er | Glipizide | 127 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 28 |
| Spironolactone | Spironolactone | 120 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 23 |
| Glipizide | Glipizide | 107 | 22 |
| Bupropion Xl | Bupropion Hcl | 104 | 27 |
| Xarelto | Rivaroxaban | 101 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 95 | 23 |
| Alendronate Sodium | Alendronate Sodium | 90 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 74 |
| Atenolol | Atenolol | 87 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 16 |
| Ozempic | Semaglutide | 84 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 27 |
| Finasteride | Finasteride | 78 | 22 |
| Memantine Hcl | Memantine Hcl | 78 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 11 |
| Januvia | Sitagliptin Phosphate | 77 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 25 |
| Amoxicillin | Amoxicillin | 68 | 37 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 13 |
| Synthroid | Levothyroxine Sodium | 68 | 13 |
| Cephalexin | Cephalexin | 66 | 47 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Alprazolam | Alprazolam | 62 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 11 |
| Famotidine | Famotidine | 55 | 14 |
| Jardiance | Empagliflozin | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 15 |
| Propranolol Hcl | Propranolol Hcl | 54 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Ezetimibe | Ezetimibe | 52 | 16 |
| Jantoven | Warfarin Sodium | 52 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Estradiol | Estradiol | 49 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Cefdinir | Cefdinir | 44 | 38 |
| Pregabalin | Pregabalin | 44 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | 13 |
| Torsemide | Torsemide | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | 11 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 24 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Dexamethasone | Dexamethasone | 35 | 34 |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Baclofen | Baclofen | 33 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 27 | 27 |
| Valsartan | Valsartan | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Topiramate | Topiramate | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 19 |
| Valacyclovir | Valacyclovir Hcl | 25 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Fluconazole | Fluconazole | 23 | 17 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Testosterone | Testosterone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.59 · 3 records | Amgen Inc. | ELIQUIS, NURTEC ODT, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error